Pharvaris’s Promising Pipeline Progress and Strong Financial Position Justify Buy Rating with $43 Target

In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Pharvaris (PHVS – Research Report), with a price target of $43.00.

Debanjana Chatterjee’s rating is based on several positive developments surrounding Pharvaris’s pipeline and financial position. The company has shown progress in its Phase 3 RAPIDe-3 study for IR deucrictibant, which is expected to yield results by the first quarter of 2026, instilling confidence in management. Additionally, the Phase 3 CHAPTER-3 study for ER deucrictibant remains on schedule for the second half of 2026, further supporting the company’s growth prospects.
Moreover, Pharvaris’s recent findings indicate that ER deucrictibant can be administered with or without food, which will be detailed at an upcoming conference, potentially broadening its application. The company’s strong cash position of €236 million, providing a runway into the third quarter of 2026, and the FDA’s waiver of the Thorough QT (TQT) study requirement, enhance its financial and regulatory standing. These factors collectively underpin Chatterjee’s Buy rating and the price target of $43.

In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $34.00 price target.